Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries

Table 2

Biochemistry, imaging, bronchoscopy, and pathology findings in bronchial NET patients diagnosed, treated, or followed-up at our institution from 1^st January 1995 to 31^st December 2015 (). Treatment refers to surgery, chemotherapy, or radiotherapy.

Parameter	Number of patients (%)
Chromogranin A (plasma)	Pre-treatment 0 (0%)
	Post-treatment 1 (2.2%)
Ki-67 (histology)	16 (34.8%)
Mitotic count (histology)	27 (58.7%)
Synaptophysin (histology)	28 (60.9%)
Chromogranin A (histology)	25 (54.3%)
CD56 (histology)	11 (23.9%)
Bronchoscopy	Pre-treatment 46 (100%)
	Post-treatment 4 (8.7%)
CT	Pre-treatment 46 (100%)
	Post-treatment 30 (65.2%)
Chest X-ray	Pre-treatment 46 (100%)
	Post-treatment 43 (93.5%)
^18F-FDG PET	Pre-treatment 18 (39.1%)
	Post-treatment 0 (0%)
Octreoscan	Pre-treatment 4 (8.7%)
	Post-treatment 2 (4.3%)

: number of patients.